About Shionogi

  1. TOP > 
  2. About Shionogi > 
  3. Company Profile > 
  4. History

History

History

movie

1897

Shionogi started to deal directly with trading firms in Europe and the US

1919

Shiono Gisaburo Shoten and Shiono Seiyakusho were merged, and the new company was named Shionogi Shoten

1922

Established the Kuise plant (now Kuise Site)

1924

Established the new head office building in Doshomachi, Osaka

1946

Established the Aburahi Laboratories in Shiga (now Aburahi Facilities)

1949

Shionogi's shares listed on the Tokyo and Osaka Stock Exchanges

1958

1961

Established Shionogi Research Laboratories in Osaka (now integrated into SPRC; Shionogi Pharmaceutical Research Center)

1963

Started veterinary drug, agricultural chemical and clinical laboratory businesses (divested in 2002, 2001 and 2002, respectively)

Established Taiwan Shionogi & Co., Ltd.

1964

Began to sponsor the TV program, Shionogi Music Fair

1968

Established the Settsu plant in Osaka

1976

Established Nichia Pharmaceutical Industries Ltd. (now Shionogi Pharma Chemicals Co., Ltd.)

1978

Celebrated our 100th year in business

1980

Established Shionogi Shibuya building in Tokyo

Established the Development Research Laboratories in Osaka (now SPRC)

1988

Established Institute for Medical Science on the Settsu plant property (now integrated into SPRC)

Launched the cephem antibiotic, Flumarin, in Japan

1992

Acquired the capsule business from Eli Lilly (divested in 2005)

Established Shionogi General Service Co., Ltd.

1993

Opened the new head office building in Doshomachi, Osaka

1997

Launched the cephem antibiotic, Flomox, in Japan

1998

The Shionogi Charter of Conduct was established

Established Ohmori Co., Ltd., a drug wholesaler (divested in 2002)

Established Bushu Pharmaceuticals Ltd. (divested in 2010)

2001

Established Shionogi USA, Inc. (now Shionogi Inc.)

Established a joint venture named Shionogi-GlaxoSmithKline Pharmaceutical LLC (later Shionogi-ViiV Healthcare LLC)
Started joint research and development, including HIV integrase inhibitors

2003

Launched the cancer pain analgesic, OxyContin, in Japan

2005

The 2nd Medium-Term Business Plan starts

Launched the hyperlipidemia treatment, Crestor, in Japan

Launched the carbapenem antibiotic, Finibax, in Japan

2007

Launched the cancer pain analgesic, OxiNorm, in Japan

Established Shionogi Analysis Center Co., Ltd.

2008

Established a joint research facility with Hokkaido University, Shionogi Innovation Center for Drug Discovery

Launched the hypertension treatment, Irbetan, in Japan

Acquired US-based Sciele Pharma, Inc. (now Shionogi Inc.)

Launched the acne vulgaris treatment, Differin, in Japan

Launched the idiopathic pulmonary fibrosis treatment, Pirespa, in Japan

2010

Launched the anti-viral drug for influenza, Rapiacta, in Japan

The 3rd Medium-Term Business Plan starts

Launched the antidepressant drug, Cymbalta, in Japan

Established the PET Molecular Imaging Center at the Osaka University Graduate School of Medicine

Established Shionogi Techno Advance Research Co., Ltd.

2011

Established a new research facility SPRC4, and integrated several research functions into SPRC

Acquired a Chinese pharmaceutical company, C&O Pharmaceutical Technology (Holdings) Limited

2012

Established a European subsidiary, Shionogi Limited in the UK

Launched the injectable cancer pain analgesic, OxiFast, in Japan

New business scheme for the HIV integrase inhibitor franchise products initiated with ViiV Healthcare

Launched the hypertension treatment, Aimix, in Japan

2013

Established Beijing Shionogi Pharmaceutical Technology Limited in China

Launched the postmenopausal vulvar and vaginal atrophy treatment, Osphena, in the US

Launched the hypertension treatment, Irtra, in Japan

Modified the Crestor royalty structure with AstraZeneca

Established Shionogi Singapore Pte. Ltd.

2014

The New Medium-Term Business Plan "SGS2020" starts

Launched the HIV treatment, Tivicay, in Japan

2015

Launched the HIV treatment, Triumeq, in Japan

Launched the desendsitization therapy, Acitair, house dust mite sublingual tablet in Japan

Launched the thrombocytopenia treatment, Mulpleta, in Japan

page top